A20 Mediated Regulation of Colitis and Spondyloarthritis
A20 介导的结肠炎和脊柱关节炎调节
基本信息
- 批准号:8436190
- 负责人:
- 金额:$ 32.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnti-Inflammatory AgentsAnti-inflammatoryArthritisBindingCD11 AntigensCell physiologyCellsColitisCrohn&aposs diseaseDataDendritic CellsEnzymesFunctional disorderGenesHomeostasisHumanHuman GeneticsITGAX geneImmuneInflammationInflammatoryInflammatory Bowel DiseasesInflammatory ResponseIntestinesLeadLinkMediatingMicrobeMolecularMouse StrainsMusPathogenesisPathway interactionsPhenotypeProductionProtein BindingProteinsPublic HealthReceptor SignalingRegulationSignal TransductionSignaling ProteinSpondylarthritisSyndromeT cell differentiationT-Cell ActivationT-LymphocyteTNF geneTestingToll-like receptorsUbiquitinUbiquitinationinhibitor/antagonistmicrobialmutantnovelpreventresponsetherapy development
项目摘要
DESCRIPTION (provided by applicant): Recent studies suggest that inflammatory bowel disease (IBD) results from the disruption of normal host immune cells responses to microbial molecules that can trigger inflammation in the intestine. Dendritic cells (DCs) are specialized immune cells that are highly sensitive to microbes and can potently activate inflammatory cells. As DCs may frequently or tonically sense the presence of microbes in the intestine, their propensity to cause inflammation may be dependent on their intracellular regulation or "interpretation" of encounters with microbes. Hence, intracellular proteins that regulate signals triggered by microbes may be central to the commitment to overt inflammatory responses. A20 is an enzyme that potently restricts signals from microbial sensing pathways, including Toll-like receptor (TLR), NOD and TNF signals. Thus, our central hypothesis is that A20 expression specifically in DCs preserves immune homeostasis and prevents IBD and IBD-associated arthritis. To test our central hypothesis, we have generated a novel strain of mice, A20FL/FL CD11c-Cre mice, in which A20 is deleted specifically from DCs. Remarkably; our preliminary data with these mice suggest that these mice spontaneously develop colitis, sero-negative arthritis and spondyloarthritis, a stereotypical syndrome in human IBD. We now propose to use these A20FL/FL CD11-cre mice to determine the cellular and molecular mechanisms linking A20 expression in DCs to these provocative phenotypes. Specifically, we will determine whether luminal microbes and T cells are involved in the pathophysiologies by which A20 deficient DCs cause colitis and arthritis (Aim 1). As A20 may restrict intracellular signals in DCs, including MyD88 dependent TLR signals, we will use compound A20FL/FL MyD88FL/FL CD11c-Cre mice to determine which A20 regulated signals in DCs are MyD88-dependent and which signals are MyD88-independent. Studies with these mice will unveil which intracellular DC signals and DC products regulate T cell activation, colitis, and sero-negative arthritis (Aim 2). A20 is a ubiquitn modifying enzyme that regulates ubiquitination of signaling proteins and also binds to A20 Binding Inhibitor of NFkB-1, or ABIN-1. To define the molecular mechanisms by which A20 and ABIN-1 may collaborate to restrict signals in DCs, we have also generated mice lacking ABIN-1 specifically in DCs. We will now use these mice to study how ABIN-1 collaborates with A20 to restrict signaling in DCs and prevent colitis and arthritis (Aim 3).
描述(由申请人提供):最近的研究表明,炎症性肠病(IBD)是由正常宿主免疫细胞对可引发肠道炎症的微生物分子的反应破坏引起的。树突状细胞(Dendritic cells,DC)是一种对微生物高度敏感的特异性免疫细胞,可以有效激活炎症细胞。由于DC可以频繁地或紧张性地感知肠道中微生物的存在,它们引起炎症的倾向可能取决于它们的细胞内调节或与微生物相遇的“解释”。因此,调节由微生物触发的信号的细胞内蛋白质可能是公开炎症反应的关键。A20是一种有效限制微生物传感途径信号的酶,包括Toll样受体(TLR)、NOD和TNF信号。因此,我们的中心假设是,A20在DC中的特异性表达保持了免疫稳态并预防IBD和IBD相关关节炎。为了验证我们的中心假设,我们已经产生了一种新的小鼠品系,A20 FL/FL CD 11 c-Cre小鼠,其中A20特异性地从DC中缺失。值得注意的是,我们对这些小鼠的初步数据表明,这些小鼠自发地发生结肠炎、血清阴性关节炎和脊椎关节炎,这是人IBD中的典型综合征。我们现在建议使用这些A20 FL/FL CD 11-cre小鼠来确定DC中A20表达与这些挑衅性表型之间的细胞和分子机制。具体而言,我们将确定是否管腔微生物和T细胞参与A20缺陷型DC引起结肠炎和关节炎的病理生理学(目的1)。由于A20可以限制DC中的细胞内信号,包括MyD 88依赖性TLR信号,我们将使用化合物A20 FL/FL MyD 88 FL/FL CD 11 c-Cre小鼠来确定DC中哪些A20调节的信号是MyD 88依赖性的,哪些信号是MyD 88不依赖性的。对这些小鼠的研究将揭示哪些细胞内DC信号和DC产物调节T细胞活化、结肠炎和血清阴性关节炎(Aim 2)。A20是一种泛素修饰酶,可调节信号蛋白的泛素化,也可与NF κ B-1或ABIN-1的A20结合抑制剂结合。为了确定A20和ABIN-1可能协作以限制DC中的信号的分子机制,我们还产生了在DC中特异性缺乏ABIN-1的小鼠。我们现在将使用这些小鼠来研究ABIN-1如何与A20合作以限制DC中的信号传导并预防结肠炎和关节炎(Aim 3)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AVERIL I MA其他文献
AVERIL I MA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AVERIL I MA', 18)}}的其他基金
Ubiquitination, Intestinal Homeostasis and Cancer
泛素化、肠道稳态和癌症
- 批准号:
10522777 - 财政年份:2022
- 资助金额:
$ 32.43万 - 项目类别:
Ubiquitination, Intestinal Homeostasis and Cancer
泛素化、肠道稳态和癌症
- 批准号:
10685627 - 财政年份:2022
- 资助金额:
$ 32.43万 - 项目类别:
A20 Mediated Regulation of Colitis and Spondyloarthritis
A20 介导的结肠炎和脊柱关节炎调节
- 批准号:
8638002 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:
A20 Mediated Regulation of Colitis and Spondyloarthritis
A20 介导的结肠炎和脊柱关节炎调节
- 批准号:
8829675 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:
A20 Mediated Regulation of Colitis and Spondyloarthritis
A20 介导的结肠炎和脊柱关节炎调节
- 批准号:
8321633 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:
UBIQUITYLATION AND THE REGULATION OF IMMUNE HOMOSTASIS
普遍性和免疫稳态的调节
- 批准号:
8363762 - 财政年份:2011
- 资助金额:
$ 32.43万 - 项目类别:
UBIQUITYLATION AND THE REGULATION OF IMMUNE HOMOSTASIS
普遍性和免疫稳态的调节
- 批准号:
8169756 - 财政年份:2010
- 资助金额:
$ 32.43万 - 项目类别:
Ubiquitylation and the Regulation of Immune Homeostasis
泛素化与免疫稳态的调节
- 批准号:
8007517 - 财政年份:2010
- 资助金额:
$ 32.43万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 32.43万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 32.43万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 32.43万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 32.43万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 32.43万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 32.43万 - 项目类别:














{{item.name}}会员




